The canonical profile remains the primary reading view. Read the canonical profile.
We added a plain-language reader guide with cited answers, re-checked the Symlin label, and added the Drugs@FDA approval record. 12
What this version reported
Large randomized, placebo-controlled trials described in the label found modest additional HbA1c reductions. The label carries a boxed warning about severe low blood sugar when used with insulin.↗
Reader guide in this version
Key takeaway
Pramlintide is a lab-made analogue of amylin, a hormone released with insulin after meals, and is the active ingredient in Symlin.1,2 It is FDA-approved as an add-on for people with type 1 or type 2 diabetes who use mealtime insulin and have not reached their blood-sugar goals despite optimal insulin therapy.1 The label carries a boxed warning that using it with insulin increases the risk of severe low blood sugar, particularly in type 1 diabetes.1
At a glance
- What it is
- An amylin analogue. The label states that it slows stomach emptying, reduces the rise in glucagon after meals and affects appetite.1
- FDA status
- FDA-approved. Drugs@FDA lists Symlin with an original approval date of March 16, 2005. The label carries a boxed warning about severe low blood sugar when used with insulin.1,2
- Human evidence
- Large randomized, double-blind, placebo-controlled trials in type 1 and type 2 diabetes, described in the label.1
- Evidence strength
- Large randomized human trials
What is pramlintide?
Pramlintide is a lab-made analogue of human amylin. The label explains that amylin is stored and released together with insulin by the pancreas in response to food, and that people with diabetes release less of both.1
In the United States it is the active ingredient of Symlin, according to Drugs@FDA.2
How does pramlintide work?
The label states that in human studies pramlintide slows stomach emptying, reduces the rise in glucagon after meals and modulates appetite, which lowers the rise in blood sugar after eating.1
The label also states that amylin suppresses glucagon release in a way that insulin alone does not normalize, and helps regulate food intake through effects on the brain.1
What do human studies show?
The label reports that 2,333 people with type 1 diabetes and 1,852 with type 2 diabetes received pramlintide in controlled clinical trials.1
In three randomized, double-blind, placebo-controlled trials in type 1 diabetes, HbA1c, a measure of long-term blood sugar, fell by 0.25 to 0.34 percentage points more with pramlintide than with placebo at 6 months, according to the label.1
In two placebo-controlled trials in type 2 diabetes in people using insulin, HbA1c fell by 0.30 to 0.34 percentage points more with pramlintide than with placebo at 6 months, according to the label.1
What the evidence base contains
- Large randomized human trial Three 26- to 52-week randomized, double-blind, placebo-controlled trials in type 1 diabetes, the largest of which randomized 480 participants to pramlintide or placebo alongside insulin.1
- Large randomized human trial Two randomized, double-blind, placebo-controlled trials in type 2 diabetes, one of which included 327 participants using insulin.1
Evidence-strength label: Large randomized human trials. How this label is assigned
Is pramlintide FDA-approved?
Yes. Drugs@FDA lists Symlin, application NDA021332, with an original approval date of March 16, 2005.2
The Symlin label cited here (DailyMed SPL version 18, published August 20, 2024) states that it is indicated as an add-on treatment for people with type 1 or type 2 diabetes who use mealtime insulin and have failed to achieve desired blood-sugar control despite optimal insulin therapy.1
The label carries a boxed warning: use with insulin increases the risk of severe low blood sugar, particularly in type 1 diabetes, usually within 3 hours, and serious injuries may occur if it happens while driving or doing other high-risk activities.1
The label states that pramlintide is contraindicated in people with serious allergic reactions to it, hypoglycemia unawareness or confirmed gastroparesis.1
What is still unknown?
Its safety and effectiveness in children, which the label says have not been established.1
Whether the modest HbA1c reductions lead to fewer long-term diabetes complications: the label’s trials report HbA1c over 6 months.1
Sources for this version
- 1SYMLINPEN (pramlintide acetate) injection · SPL version 18 · published 2024-08-20 ↗
DailyMed · U.S. National Library of Medicine · Official source · Source checked July 22, 2026
- 2Drugs@FDA application NDA021332 · original submission status AP · 2005-03-16 · dataset 2026-08-13 ↗
Drugs@FDA via openFDA · Official source · Source checked August 14, 2026